Klin Onkol 2016; 29(1): 63-65. DOI: 10.14735/amko201663.
Targeted therapy of lung cancer has brought signifi cant improvement in prognosis for a lot
of patients with EGFR-sensitive mutations and ALK translocations. Other clinical studies have
shown ROS1 translocation as another potential target. Our case report brings probably the
fi rst successful use of crizotininib in a patient with ROS1 translocation in the Czech Republic.
Treatment was well-tolerated and persists continually. During the control PET/ CT scans, partial
regression of the disease was observed. ROS1 translocation becomes another promising target
for our patients. Therefore, in our opinion, serious discussion about its inclusion among the
basic genetic testing in lung adenocarcinomas should occur.
